Abstract: The pathogenesis of nail lichen planus is unclear, and lack of clear drug guidance. It has been reported that glucocorticoids, avitamin A, immunosuppressants (such as methotrexate, cyclosporine, morpheolate), biologics (such as etanercept), and sulfoxone have certain effects on the treatment of lichenus planus, but most of them can only alleviate. Recent studies have found that the JAK/STAT signaling pathway may play an important role in the pathogenesis of nail lichen planus, and 4 cases of JAK inhibitor treatment have been reported. This paper reports a case which the JAK inhibitor tofacitinib citrate sustained release tablets were used to treat onychlichen planus. After 4 months, partial onychia damage was improved and new nail growth was observed.

Key words: nail lichen planus')">">nail lichen planus, tofacitinib